RecruitingPhase 1NCT07539090

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) in Healthy Female Participants

Sponsor

Deciphera Pharmaceuticals, LLC

Enrollment

24 participants

Start Date

Jun 5, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Participants

Summary

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) and a drug called Vimseltinib for people with healthy participants. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVimseltinib

Administered orally

DRUGCombined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])

Administered orally

Locations(1)

Nucleus Network

Saint Paul, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07539090

Related Trials

Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance

NCT07769489

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

NCT07793019

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT075112053 locations

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

NCT076265151 location

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

NCT07751250